MedTrace Logo

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

NCT01483027 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 428

Last updated 2022-03-29

Study results available
· View outcomes & findings →

Summary

The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.

Conditions

  • Colorectal Cancer Metastatic

Interventions

DEVICE

TheraSphere

yttrium 90 microspheres

Sponsors & Collaborators

  • Biocompatibles UK Ltd

    collaborator INDUSTRY

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Mary F Mulcahy, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • China
  • France
  • Germany
  • Italy
  • Poland
  • Singapore
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01483027 on ClinicalTrials.gov